嘉应制药
(002198)
| 流通市值：33.19亿 | | | 总市值：33.19亿 |
| 流通股本：5.07亿 | | | 总股本：5.08亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 293,436,251.95 | 198,937,664.09 | 121,632,944.06 | 376,167,156.57 |
| 营业收入 | 293,436,251.95 | 198,937,664.09 | 121,632,944.06 | 376,167,156.57 |
| 二、营业总成本 | 266,450,162.51 | 174,323,616.04 | 101,544,275.2 | 349,185,997.89 |
| 营业成本 | 127,900,707.65 | 74,509,094.31 | 40,369,560.36 | 150,722,980.96 |
| 税金及附加 | 5,040,226.45 | 3,394,073.61 | 1,962,224.32 | 7,188,491.9 |
| 销售费用 | 102,135,556.53 | 72,435,897.48 | 44,206,430.98 | 137,401,217.09 |
| 管理费用 | 24,538,945.5 | 19,460,130.48 | 13,474,828.62 | 48,485,607.56 |
| 研发费用 | 7,167,677.83 | 4,813,656.5 | 1,699,113.63 | 6,757,234.58 |
| 财务费用 | -332,951.45 | -289,236.34 | -167,882.71 | -1,369,534.2 |
| 其中:利息费用 | - | - | - | 3,955.04 |
| 其中:利息收入 | 402,723.88 | 318,516.76 | 182,881.75 | 1,408,500.11 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | -361,667.6 | -499,543 | - |
| 加:投资收益 | -117,195.03 | 415,663.13 | -352,280 | 675,010.43 |
| 资产处置收益 | -134,617.2 | 120.92 | 120.92 | 1,606,951.4 |
| 资产减值损失(新) | - | - | - | -1,190,339.63 |
| 信用减值损失(新) | -1,296,086.72 | -1,296,086.72 | - | -4,030,242.59 |
| 其他收益 | 202,295.95 | 129,182.39 | 90,263.76 | 1,215,061.69 |
| 四、营业利润 | 25,640,486.44 | 23,501,260.17 | 19,327,230.54 | 25,257,599.98 |
| 加:营业外收入 | 169,539.97 | 165,617.82 | 99,002.13 | 291,258.51 |
| 减:营业外支出 | 69,020.47 | 69,002.13 | 86,919.96 | 453,781.12 |
| 五、利润总额 | 25,741,005.94 | 23,597,875.86 | 19,339,312.71 | 25,095,077.37 |
| 减:所得税费用 | 3,946,708.24 | 3,515,316.38 | 3,936,055.53 | 4,483,477.82 |
| 六、净利润 | 21,794,297.7 | 20,082,559.48 | 15,403,257.18 | 20,611,599.55 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 21,794,297.7 | 20,082,559.48 | 15,403,257.18 | 20,611,599.55 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 21,794,297.7 | 20,082,559.48 | 15,403,257.18 | 20,611,599.55 |
| 扣除非经常损益后的净利润 | 20,142,508.67 | 18,788,637.68 | 15,751,018.59 | 14,552,294.96 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.04 | 0.04 | 0.03 | 0.04 |
| (二)稀释每股收益 | 0.04 | 0.04 | 0.03 | 0.04 |
| 八、其他综合收益 | -1,011,000 | -1,062,500 | - | - |
| 归属于母公司股东的其他综合收益 | -1,011,000 | -1,062,500 | - | - |
| 九、综合收益总额 | 20,783,297.7 | 19,020,059.48 | 15,403,257.18 | 20,611,599.55 |
| 归属于母公司股东的综合收益总额 | 20,783,297.7 | 19,020,059.48 | 15,403,257.18 | 20,611,599.55 |
| 公告日期 | 2025-10-29 | 2025-08-26 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |